{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T21:16:00Z","timestamp":1774127760297,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003107","name":"German Federal Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.vaccine.2025.127987","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T05:44:54Z","timestamp":1763617494000},"page":"127987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative analysis of a flexible novel vaccine platform based on cell permeable chimeric HBV capsids for mucosal vaccination"],"prefix":"10.1016","volume":"69","author":[{"given":"Jan","family":"Raupach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Younes","family":"Housria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Hein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Schnierle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilal","family":"Durmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberhard","family":"Hildt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127987_bb0005","author":"WHO"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127987_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9070747","article-title":"Accelerated development of COVID-19 vaccines: technology platforms, benefits, and associated risks","volume":"9","author":"Wagner","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127987_bb0015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/all.14868","article-title":"Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe","volume":"77","author":"Wagner","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127987_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127987_bb0025","doi-asserted-by":"crossref","first-page":"2520861","DOI":"10.1080\/20523211.2025.2520861","article-title":"A scoping review of authorisation pathway for COVID-19 vaccines among selected countries","volume":"18","author":"Suphap","year":"2025","journal-title":"Journal of pharmaceutical policy and practice"},{"key":"10.1016\/j.vaccine.2025.127987_bb0030","series-title":"Immunobiology 5: The immune system in health and disease","author":"Janeway","year":"2001"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127987_bb0035","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.4161\/hv.24961","article-title":"Public trust and vaccine acceptance--international perspectives","volume":"9","author":"Ozawa","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127987_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13020140","article-title":"Strategies for vaccination: conventional vaccine approaches versus new-generation strategies in combination with adjuvants","volume":"13","author":"Bouazzaoui","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127987_bb0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12033-012-9598-4","article-title":"Construction and characterization of virus-like particles: a review","volume":"53","author":"Zeltins","year":"2013","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2025.127987_bb0050","article-title":"Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases","volume":"12","author":"Tariq","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2025.127987_bb0055","doi-asserted-by":"crossref","first-page":"1123805","DOI":"10.3389\/fimmu.2023.1123805","article-title":"Platforms, advances, and technical challenges in virus-like particles-based vaccines","volume":"14","author":"Gupta","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127987_bb0060","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1134\/S0026893316040099","article-title":"The true story and advantages of the famous hepatitis B virus core particles: outlook 2016","volume":"50","author":"Pumpens","year":"2016","journal-title":"Mol Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127987_bb0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1586\/erv.12.150","article-title":"Hepatitis B core-based virus-like particles to present heterologous epitopes","volume":"12","author":"Roose","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"15","key":"10.1016\/j.vaccine.2025.127987_bb0070","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1021\/bi00015a003","article-title":"Hepatitis core antigen produced in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid assembly","volume":"34","author":"Wingfield","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.vaccine.2025.127987_bb0075","series-title":"Dimorphism of Hepatitis B Virus Capsids Is Strongly Influenced by the C-Terminus of the Capsid Protein","author":"Zlotnick","year":"2025"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127987_bb0080","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s007260070072","article-title":"Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble","volume":"18","author":"Karpenko","year":"2000","journal-title":"Amino Acids"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127987_bb0085","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1073\/pnas.96.5.1915","article-title":"Native display of complete foreign protein domains on the surface of hepatitis B virus capsids","volume":"96","author":"Kratz","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"41","key":"10.1016\/j.vaccine.2025.127987_bb0090","doi-asserted-by":"crossref","first-page":"43281","DOI":"10.18632\/oncotarget.6533","article-title":"Hepatitis B virus core antigen as a carrier for chlamydia trachomatis MOMP multi-epitope peptide enhances protection against genital chlamydial infection","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127987_bb0095","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.virol.2004.02.022","article-title":"An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice","volume":"323","author":"Geldmacher","year":"2004","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127987_bb0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000346773","article-title":"Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures","volume":"56","author":"Pushko","year":"2013","journal-title":"Intervirology"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127987_bb0105","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/hep.20950","article-title":"A novel system for efficient gene transfer into primary human hepatocytes via cell-permeable hepatitis B virus-like particle","volume":"42","author":"Brandenburg","year":"2005","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127987_bb0110","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1038\/s41598-017-08787-0","article-title":"Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8+ T-cell response","volume":"7","author":"Akhras","year":"2017","journal-title":"Sci Rep"},{"issue":"15","key":"10.1016\/j.vaccine.2025.127987_bb0115","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1016\/j.vaccine.2020.02.063","article-title":"A new approach for therapeutic vaccination against chronic HBV infections","volume":"38","author":"Zahn","year":"2020","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127987_bb0120","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/sj.gt.3301154","article-title":"Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens","volume":"7","author":"Oess","year":"2000","journal-title":"Gene Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127987_bb0125","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00018-005-5548-7","article-title":"The translocation motif of hepatitis B virus improves protein vaccination","volume":"63","author":"Bleifuss","year":"2006","journal-title":"Cellular and molecular life sciences CMLS"},{"issue":"34","key":"10.1016\/j.vaccine.2025.127987_bb0130","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1021\/bi500732b","article-title":"The hepatitis B virus core protein intradimer interface modulates capsid assembly and stability","volume":"53","author":"Selzer","year":"2014","journal-title":"Biochemistry"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127987_bb0135","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/all.15189","article-title":"Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses","volume":"77","author":"Hein","year":"2022","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127987_bb0140","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/acs.biochem.1c00810","article-title":"Hysteresis in hepatitis B virus (HBV) requires assembly of near-perfect capsids","volume":"61","author":"Starr","year":"2022","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127987_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069729","article-title":"3.5\u00c5 cryoEM structure of hepatitis B virus core assembled from full-length core protein","volume":"8","author":"Yu","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127987_bb0150","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.virol.2004.11.019","article-title":"Calcium ions affect the hepatitis B virus core assembly","volume":"332","author":"Choi","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.127987_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.929243","article-title":"Effects of different lengths of a nucleic acid binding region and bound nucleic acids on the phase behavior and purification process of HBcAg virus-like particles","volume":"10","author":"Valentic","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127987_bb0160","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S1097-2765(01)80009-5","article-title":"The crystal structure of the human hepatitis B virus capsid","volume":"3","author":"Wynne","year":"1999","journal-title":"Mol Cell"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127987_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202100422","article-title":"Designed SARS-CoV-2 receptor binding domain variants form stable monomers","volume":"17","author":"Klausberger","year":"2022","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2025.127987_bb0170","first-page":"310","article-title":"Prediction of glycosylation across the human proteome and the correlation to protein function","author":"Gupta","year":"2002","journal-title":"Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing"},{"issue":"21","key":"10.1016\/j.vaccine.2025.127987_bb0175","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.1021\/bi9803123","article-title":"Energetic roles of hydrogen bonds at the ureido oxygen binding pocket in the streptavidin-biotin complex","volume":"37","author":"Klumb","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.vaccine.2025.127987_bb0180","series-title":"Site-specific biotinylation of purified proteins using BirA. Methods in molecular biology (Clifton, N.J.)","first-page":"171","volume":"1266","author":"Fairhead","year":"2015"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127987_bb0185","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.chembiol.2021.07.005","article-title":"DogCatcher allows loop-friendly protein-protein ligation","volume":"29","author":"Keeble","year":"2022","journal-title":"Cell chemical biology"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127987_bb0190","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12951-018-0363-0","article-title":"Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide","volume":"16","author":"Schumacher","year":"2018","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.vaccine.2025.127987_bb0200","doi-asserted-by":"crossref","first-page":"26523","DOI":"10.1073\/pnas.1909653116","article-title":"Approaching infinite affinity through engineering of peptide-protein interaction","author":"Keeble","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127987_bb0205","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jmb.2014.09.026","article-title":"The CamSol method of rational design of protein mutants with enhanced solubility","volume":"427","author":"Sormanni","year":"2015","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2025.127987_bb0210","series-title":"Influence of polymer in the adjuvanticity of microencapsulated CpG oligodeoxynucleotides","author":"Sanroman","year":"2025"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2025.127987_bb0215","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.imbio.2004.02.006","article-title":"C-class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level","volume":"209","author":"Jurk","year":"2004","journal-title":"Immunobiology"},{"key":"10.1016\/j.vaccine.2025.127987_bb0230","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2025.127987_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.837443","article-title":"A thermostable Oral SARS-CoV-2 vaccine induces mucosal and protective immunity","volume":"13","author":"Bellier","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127987_bb0255","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.imlet.2023.05.007","article-title":"Inactivated COVID-19 vaccines: potential concerns of antibody-dependent enhancement and original antigenic sin","volume":"259","author":"Kan","year":"2023","journal-title":"Immunol Lett"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127987_bb0260","article-title":"Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component","volume":"6","author":"Su","year":"2024","journal-title":"JHEP reports innovation in hepatology"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127987_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8010128","article-title":"Better adjuvants for better vaccines: Progress in adjuvant delivery systems, modifications, and adjuvant-antigen Codelivery","volume":"8","author":"Wang","year":"2020","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127987_bb0270","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14760584.2023.2238807","article-title":"In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives","volume":"22","author":"Zeng","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127987_bb0275","doi-asserted-by":"crossref","first-page":"1107803","DOI":"10.3389\/fimmu.2023.1107803","article-title":"Defending against SARS-CoV-2: the T cell perspective","volume":"14","author":"Almendro-V\u00e1zquez","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127987_bb0280","doi-asserted-by":"crossref","first-page":"2287118","DOI":"10.1080\/22221751.2023.2287118","article-title":"The characterization of CD8+ T-cell responses in COVID-19","volume":"13","author":"Yang","year":"2024","journal-title":"Emerging microbes & infections"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2501285X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2501285X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T07:29:07Z","timestamp":1765351747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2501285X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"alternative-id":["S0264410X2501285X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127987","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of a flexible novel vaccine platform based on cell permeable chimeric HBV capsids for mucosal vaccination","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127987"}}